<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302508</url>
  </required_header>
  <id_info>
    <org_study_id>14.143</org_study_id>
    <nct_id>NCT02302508</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients</brief_title>
  <acronym>PANDDA</acronym>
  <official_title>PANDDA Study: Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue
      to show an increased risk of adverse cardiovascular events and mortality compared to those
      without T2D.The aim of the first project is to describe the pharmacokinetic (PK) profile of
      three antiplatelet drugs in 4 groups of patients according to their diabetic or non-diabetic
      status. To this end, PK profiles will be determined after a single oral dose of 300 mg
      clopidogrel, 60 mg prasugrel and 180 mg ticagrelor in patients (n=108); 1) with T2D and good
      glycemic control; 2) with T2D and poor glycemic control; 3) with insulin-treated diabetes;
      and 4) non-diabetic subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel efficacy appears diminished in patients with T2D who continue to show an
      increased risk of adverse cardiovascular events and mortality compared to those without T2D.
      To the contrary, response to prasugrel and ticagrelor appears conserved in ACS patients with
      diabetes. There are several mechanisms that may be contributing to the blunted response to
      clopidogrel but a postulated decreased concentration of clopidogrel active metabolite is
      worth pursuing further.

      The overall objective of this proposal is to describe the pharmacokinetic profiles of three
      antiplatelet drugs namely, clopidogrel, prasugrel and ticagrelor in four groups of patients
      according to their diabetic or non-diabetic status.

      Patients (n=108) will be recruited to constitute 4 groups: Group I, 27 confirmed T2D with A1C
      ≤7; Group II, 27 patients with poor glycemic control A1C Patients (n=108) will be recruited
      to constitute 4 groups: Group I, 27 confirmed T2D with A1C &lt;7.0; Group II, 27 patients with
      poor glycemic control A1C &gt;7.5; Group III, 27 patients with insulin-treated T2D; and Group
      IV, 27 sex-matched non-diabetic healthy subjects. Subjects with type 2 diabetes according to
      the Canadian Clinical Guidelines will be recruited at the CHUM outpatient clinic. After an
      overnight fast, participants will be admitted to the CRCHUM's Clinical Research Unit (they
      will not be hospitalized). A crossover randomized study design with 3 phases (washout period
      of 12 days between phases) will be conducted. Subjects will receive a single oral dose of
      clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3
      different occasions. Serial blood samples will be drawn and urine collected over 10 hours (PK
      and PD analysis).

      A blood sample will be taken for pharmacogenetic analyses. Additional blood samples will be
      collected just before the administration of antiplatelet drugs to measure fasting insulin,
      glycaemia levels to determine the HOMA-IR. In addition, the following covariates namely,
      gender, age, weight, duration of diabetes and drug profile will be also recorded.

      Their regular medication will be administered 4 hours after the administration of the
      antiplatelet drug.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC0-t metabolites and parent drug) of clopidogrel, prasugrel and ticagrelor.</measure>
    <time_frame>30 days</time_frame>
    <description>The association between the T2D effects on antiplatelet drug's PK (AUC0-t metabolites, AUC0-t of parent drug) will be assessed after a single oral loading dose in patients with different diabetic status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet function activities</measure>
    <time_frame>30 days</time_frame>
    <description>Platelet function reactivity (pharmacodynamic) will be compared between antiplatelet agents and groups of patients.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>T2D patients with A1C ≤7.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D patients with A1C&gt;7.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulino-treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic healthy subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel, Prasugrel, Ticagrelor</intervention_name>
    <description>PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents</description>
    <arm_group_label>T2D patients with A1C ≤7.0</arm_group_label>
    <arm_group_label>T2D patients with A1C&gt;7.5</arm_group_label>
    <arm_group_label>Insulino-treated</arm_group_label>
    <arm_group_label>Non-diabetic healthy subjects</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>Brilinta</other_name>
    <other_name>Effient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants will be ≥18 years old

          -  Non-smokers (&gt;3 months)

          -  T2D with good glycemic control A1C&lt;7.0

          -  T2D with poor glycemic control A1C &gt;7.5

          -  Insulin-treated T2D

          -  Non-diabetic healthy subjects

        Exclusion Criteria:

          -  Subjects with estimated glomerular filtration (MDRD) &lt;50 mL/min/1.73m2

          -  ALT and AST 3 times above the upper limit of normal

          -  Organ transplant recipients

          -  Inflammatory illnesses (i.e., polyarthritis, hepatitis, cirrhosis, active infectious
             diseases)

          -  Active cancer (except non-melanoma skin cancer)

          -  Uncontrolled thyroid functions

          -  Inflammatory bowel diseases (ulcerous colitis and Crohn's disease), bariatric surgery

          -  Pregnancy

          -  History of drug or alcohol abuse

          -  Platelet function disorder,

          -  One of the following therapies : P2Y12 inhibitors, antithrombotics, antibiotics,
             anticoagulant, antivirals, CYP450 inducers (carbamazepine, phenobarbital, phenytoin,
             rifampin, St-John's worth), CYP450 inhibitors (amiodarone, fluoxetine, verapamil),
             immunosuppressors, INFs, or grapefruit juice (&lt;4 weeks) or an investigational drug

          -  Intolerance or hypersensitivity to antiplatelet drugs or their excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique Michaud, BPharm. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre Hospitalier de l'université de Montréal (CHUM)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronique Michaud, BPharm. PhD</last_name>
    <phone>5148908000</phone>
    <phone_ext>15812</phone_ext>
    <email>v.michaud@umontreal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacques Turgeon, BPharm. PhD</last_name>
    <phone>5148908045</phone>
    <email>jacques.turgeon@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>drug metabolism</keyword>
  <keyword>platelet reactivity</keyword>
  <keyword>carboxylesterase</keyword>
  <keyword>cytochromes p450</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>active metabolite</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

